Gene And Cell Therapy Products Community

View Only

Back to Library

Risk vs Benefit of CART therapies :FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies.

Recommend

01-25-2024 23:15

Vibha Jawa

Statistics

0 Favorited

9 Views

1 Files

0 Shares

4 Downloads

Attachment(s)

Secondary malignancy CAR T result NEJM.pdf 356 KB 1 version
Uploaded - 01-25-2024

Download